» Articles » PMID: 22932223

Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia

Overview
Journal Sci Transl Med
Date 2012 Aug 31
PMID 22932223
Citations 426
Authors
Affiliations
Soon will be listed here.
Abstract

Given that most bone marrow cells are short-lived, the accumulation of multiple leukemogenic mutations in a single clonal lineage has been difficult to explain. We propose that serial acquisition of mutations occurs in self-renewing hematopoietic stem cells (HSCs). We investigated this model through genomic analysis of HSCs from six patients with de novo acute myeloid leukemia (AML). Using exome sequencing, we identified mutations present in individual AML patients harboring the FLT3-ITD (internal tandem duplication) mutation. We then screened the residual HSCs and detected some of these mutations including mutations in the NPM1, TET2, and SMC1A genes. Finally, through single-cell analysis, we determined that a clonal progression of multiple mutations occurred in the HSCs of some AML patients. These preleukemic HSCs suggest the clonal evolution of AML genomes from founder mutations, revealing a potential mechanism contributing to relapse. Such preleukemic HSCs may constitute a cellular reservoir that should be targeted therapeutically for more durable remissions.

Citing Articles

Prognostic impact of TET2 mutations in patients with acute myeloid leukemia: HM-SCREEN-Japan 01 and 02 study.

Iyama S, Chi S, Idogawa M, Ikezoe T, Fukushima K, Utsu Y Ann Hematol. 2025; 104(1):275-284.

PMID: 39921715 PMC: 11868205. DOI: 10.1007/s00277-025-06227-y.


Single-cell DNA sequencing reveals pervasive positive selection throughout preleukemic evolution.

Poon G, Vedi A, Sanders M, Laurenti E, Valk P, Blundell J Cell Genom. 2025; 5(2):100744.

PMID: 39842433 PMC: 11872528. DOI: 10.1016/j.xgen.2024.100744.


Advancing Chimeric Antigen Receptor T-Cell Therapy for Acute Myeloid Leukemia: Current Limitations and Emerging Strategies.

Damiani D, Tiribelli M Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770471 PMC: 11728840. DOI: 10.3390/ph17121629.


TIM-3 marks measurable residual leukemic stem cells responsible for relapse after allogeneic stem cell transplantation.

Sakoda T, Kikushige Y, Irifune H, Kawano G, Harada T, Semba Y Cancer Sci. 2024; 116(3):698-709.

PMID: 39726280 PMC: 11875787. DOI: 10.1111/cas.16431.


The Crossroads of Clonal Evolution, Differentiation Hierarchy, and Ontogeny in Leukemia Development.

Sturgeon C, Wagenblast E, Izzo F, Papapetrou E Blood Cancer Discov. 2024; 6(2):94-109.

PMID: 39652739 PMC: 11876951. DOI: 10.1158/2643-3230.BCD-24-0235.


References
1.
Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M . Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009; 114(1):144-7. PMC: 2710942. DOI: 10.1182/blood-2009-03-210039. View

2.
Weissman I . Stem cell research: paths to cancer therapies and regenerative medicine. JAMA. 2005; 294(11):1359-66. DOI: 10.1001/jama.294.11.1359. View

3.
Taussig D, Vargaftig J, Miraki-Moud F, Griessinger E, Sharrock K, Luke T . Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood. 2010; 115(10):1976-84. PMC: 2837317. DOI: 10.1182/blood-2009-02-206565. View

4.
Greaves M . Darwin and evolutionary tales in leukemia. The Ham-Wasserman Lecture. Hematology Am Soc Hematol Educ Program. 2009; :3-12. DOI: 10.1182/asheducation-2009.1.3. View

5.
Jamieson C, Ailles L, Dylla S, Muijtjens M, Jones C, Zehnder J . Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004; 351(7):657-67. DOI: 10.1056/NEJMoa040258. View